<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01268813</url>
  </required_header>
  <id_info>
    <org_study_id>METASC011</org_study_id>
    <nct_id>NCT01268813</nct_id>
  </id_info>
  <brief_title>Personalized Medicine for Diabetes Prediction and Prevention of Complications</brief_title>
  <official_title>Personalized Medicine in Diabetes Using a Nanotechnology Platform</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Technion, Israel Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The metabolic syndrome is a collection of related risk factors that predispose to the
      development of type 2 diabetes Mellitus and cardiovascular disease. The investigators will
      examine the hypothesis that the metabolic and genomic characteristics of patients with
      metabolic syndrome and/or diabetes that are at risk for developing complications differ from
      each other and can be detected using specific biomarkers in blood or in the exhaled breath.
      Early detection of these individuals will enable personalized treatment to prevent and treat
      diabetes and its complications
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breath samples will be collected in inert respiratory bag from diabetic and healthy
      volunteers, and analyzed using a chamber containing nano-chemical sensors. These samples
      together with blood samples will additionally be characterized using Gas Chromatography-Mass
      Spectroscopy &quot;GC-MS&quot;.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">March 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of Diabetes or complication</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Exhaled breath uptake blood test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diabetic patients receiving oral hypoglycemic drug will be tested for biomarkers in their breath and blood samples</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exhaled breath and blood test</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Breath and blood samples will be collected from healthy volunteers and analyzed using Gas Chromatography-Mass Spectroscopy. The results will be compared to the experimental arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Breath analysis and blood analysis</intervention_name>
    <description>Exhaled breath and blood samples will be collected and further tested using Gas Chromatography-Mass Spectroscopy system.</description>
    <arm_group_label>Exhaled breath uptake blood test</arm_group_label>
    <arm_group_label>Exhaled breath and blood test</arm_group_label>
    <other_name>nanothecnology platform</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metabolic Syndrome

          -  Type 2 diabetes

          -  Healthy volunteers with 20&lt;Body Mass Index&lt;25

        Exclusion Criteria:

          -  Smoking

          -  Chronic or acute lung disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eddy Karnieli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Medicl Center, Technion</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eddy Karnieli, MD</last_name>
    <phone>+97248541606</phone>
    <email>eddy@rambam.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Margalit Levy, BA</last_name>
    <phone>+97248541606</phone>
    <email>endo@rambam.health.gov.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rambam Medical Center - Inst. Endocrinology, Diabetes &amp; Metabolism</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Eddy Karnieli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sagit Zolotov, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2010</study_first_submitted>
  <study_first_submitted_qc>December 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2010</study_first_posted>
  <last_update_submitted>December 30, 2010</last_update_submitted>
  <last_update_submitted_qc>December 30, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. Eddy Karnieli</name_title>
    <organization>Rambam Medical Center</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

